2 recruiting. 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow J-Pharma Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer Nanvuranlat, Physician's Best Choice - Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC) | Phase 3 | Recruiting | J-Pharma Co., Ltd. | 480 | 2026-05-11 | 2026-09-29 |
| A Study of JPH034 in Healthy Adult Participants JPH034, Placebo Control - Health Adult Subjects | Phase 1 | Recruiting | J-Pharma Co., Ltd. | 40 | 2026-03-22 | 2026-08-06 |
Biliary Tract Neoplasms (1) · Cholangiocarcinoma (1) · Gallbladder Neoplasms (1)
Folfox protocol (1) · Irinotecan (1) · Leucovorin (1) · Oxaliplatin (1)
United States (2)
Eric K Rowinsky, MD (1) · Ghassan Abou-Alfa, MD (1)